Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$79.29 USD

79.29
1,466,257

-1.20 (-1.49%)

Updated Nov 7, 2024 03:59 PM ET

After-Market: $79.32 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks News

Hill Rom Impresses with Q2 Results, Strategic Initiatives

On May 18, we issued an updated research report on Hill Rom Holdings, Inc. (HRC).

    Mazor Robotics at a 52-Week High: What's Driving the Stock?

    Shares of Israel-based developer of robotic technology and products, Mazor Robotics Ltd. (MZOR), rallied to a new 52-week high of $45.64 on May 18.

      Exactech (EXAC) Gets FDA Approval for ExactechGPS Application

      Exactech Inc. (EXAC) recently announced that it has received clearance from the U.S. Food and Drug Administration to market its proprietary ExactechGPS Shoulder Application in US.

        Boston Scientific's Symetis Buyout Boosts Structural Heart

        Boston Scientific Corporation (BSX) recently completed the acquisition of Switzerland-based Symetis SA.

          Medtronic's MyCareLink Data on Older Patients Found Positive

          Medtronic plc (MDT) recently released favorable data on its app-based remote cardiac monitoring.

            Halyard Health Announces New Drainage System, Stock Down

            Halyard Health (HYH), a leading medical technology company, recently announced the availability of the Halyard Enteral Drainage System, a significant addition to the company's comprehensive portfolio of enteral feeding products.

              Boston Scientific Hits a 52-Week High on Solid Prospects

              Share price of Natick, MA-based Boston Scientific Corporation (BSX) reached a new 52-week high of $26.76 on May 16, eventually closing a bit lower at $26.48.

                Abbott Lab Well Poised on Strong EPD, St. Jude Integration

                On May 17, we issued an updated research report on Abbott Laboratories (ABT).

                  Genomic Health Q1 Results Weak, Cancer Test Business Strong

                  On May 16, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX).

                    Edwards Lifesciences SAPIEN 3 Heart Valve Data Positive

                    Edwards Lifesciences Corporation (EW) recently unveiled positive one-year data on its SAPIEN 3 transcatheter heart valve.

                      Evolent Health (EVH) Prices 7M Follow-On Share Offering

                      Evolent Health, Inc. (EVH) recently announced the pricing of its follow-on public offering of 7.5 million shares of Class A common stock at $24.65 per share.

                        Genomic Health's (GHDX) Oncotype DX GPS Test Data Positive

                        Genomic Health, Inc. (GHDX), a global cancer company, recently presented positive results for its Oncotype DX Genomic Prostate Score (GPS) test.

                          Teleflex to Introduce Arrow AC3 Optimus at EuroPCR, Paris

                          Teleflex Inc. (TFX) announced plans to introduce Arrow AC3 Optimus Intra-Aortic Balloon Pump at the European Association for Percutaneous Cardiovascular Interventions Course (EuroPCR) in Paris during May 16--19.

                            Thermo Fisher (TMO) to Buy Patheon, Expand in Biopharma

                            Thermo Fisher Scientific Inc. (TMO), a leading scientific instrument maker, recently agreed to acquire Netherlands-based Patheon N.V.

                              Medtronic ICMs Detect High Rate of AF in Undiagnosed Patients

                              Medical device major Medtronic plc (MDT) recently unveiled results from a new clinical study evaluating Insertable Cardiac Monitors (ICMs).

                                CR Bard (BCR) Hits a 52-Week High: What's Driving the Stock?

                                Shares of CR Bard (BCR), also known as Bard, rallied to a new 52-week high of $309.16 on May 12. Let us take a look at the key catalysts driving the stock's performance.

                                  Hologic (HOLX) Tops Q2 Earnings & Sales, Raises 2017 View

                                  Hologic Inc. (HOLX) reported second-quarter fiscal 2017 adjusted earnings per share (EPS) of 50 cents, up 6.4% year over year.

                                    Varian ProBeam Proton System Gets Okayed by Shonin in Japan

                                    Varian Medical Systems, Inc. (VAR) recently announced that its flagship ProBeam system for proton therapy has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW)

                                      Inogen (INGN) Beats Earnings and Revenue Estimates in Q1

                                      Inogen (INGN) reported a stellar first quarter of 2017, beating the Zacks Consensus Estimate for both the counts. The company witnessed solid growth in revenues and adjusted earnings on a year-over-year basis.

                                        STERIS (STE) Tops Q4 Earnings & Revenues, Issues '18 View

                                        STERIS Plc (STE) reported fourth-quarter fiscal 2017 adjusted earnings per share (EPS) of $1.11, up 23.3% from the year-ago quarter.

                                          Abiomed (ABMD) Q4 Earnings Meet, Revenues Beat Estimates

                                          Abiomed Inc. (ABMD), a leading developer, manufacturer and marketer of medical products, reported fourth-quarter fiscal 2017 earnings of 33 cents per share, which were in line with the Zacks Consensus Estimate.

                                            Penumbra (PEN) Q1 Loss Wider than Expected, View Intact

                                            Penumbra, Inc. (PEN), that went public in Sep 2015, reported first-quarter 2017 loss of 10 cents per share, comparing unfavorably with earnings of 7 cents year over year.

                                              PetMed (PETS) Beats Earnings, Revenue Estimates in Q4

                                              PetMed Express, Inc. (PETS) announced earnings per share of 37 cents for the fourth quarter of fiscal 2017, up 37% from the year-ago quarter's 27 cents.

                                                Henry Schein (HSIC) Tops Q1 Earnings, Reaffirms '17 View

                                                Henry Schein, Inc. (HSIC) reported adjusted earnings per share (EPS) of $1.76 in the first quarter of 2017, up 24.8% year over year.

                                                  Haemonetics (HAE) Tops Q4 Earnings, Sales, Issues 2018 View

                                                  Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 39 cents in the fourth quarter of fiscal 2017, up 5.4% year over year.